Article
Open Access
Volume 5 · Issue 3 · 2025
pp. 75–80
Assessment of the Relationship Between JAK2 V617F Mutation Status and Plasma Viscosity in Polycythemia Vera Patients
Efe Hasdemir1 
, Selami Koçak Toprak2 , Ebru Koca3
, Selami Koçak Toprak2 , Ebru Koca3
1
Department of Medical Oncology, Artvin State Hospital, Artvin, Türkiye
2
Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Türkiye
3
Department of Hematology, Faculty of Medicine, Başkent University, Ankara, Türkiye
Abstract
Objectives: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by the clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. In this study, we aimed to evaluate the association between plasma viscosity, a potential risk factor for thrombotic complications, and the JAK2 V617F muta-tion.
Methods: Patients were classified into two subgroups: JAK2 V617F mutation-positive and JAK2 V617F-negative patients. A total of 60 patients were enrolled in the study, of whom 31 were JAK2 V617F-positive and 29 were negative. In addi-tion, we evaluated fibrinogen, albumin, erythrocyte sedimentation rate, and C-reactive protein (CRP) levels.
Results: Plasma viscosity values in JAK2 V617F mutation-positive patients and JAK2 V617F mutation-negative patients were found to be 1.089±0.126 mPa·s and 1.098±0.111 mPa·s, respectively (p=0.782). There was no relationship between plasma viscosity levels and the JAK2 V617F mutation in polycythemia vera. In correlation analyses, fibrinogen was cor-related with plasma viscosity in both groups (r=0.30, r=0.15). In addition, the erythrocyte sedimentation rate was cor-related with plasma viscosity in both groups (r=0.230, r=0.272).
Conclusion: We were unable to demonstrate a relationship between plasma viscosity and the JAK2 V617F mutation in patients with polycythemia vera. This study shows that plasma viscosity is affected by fibrinogen and other acute-phase reactants.
Methods: Patients were classified into two subgroups: JAK2 V617F mutation-positive and JAK2 V617F-negative patients. A total of 60 patients were enrolled in the study, of whom 31 were JAK2 V617F-positive and 29 were negative. In addi-tion, we evaluated fibrinogen, albumin, erythrocyte sedimentation rate, and C-reactive protein (CRP) levels.
Results: Plasma viscosity values in JAK2 V617F mutation-positive patients and JAK2 V617F mutation-negative patients were found to be 1.089±0.126 mPa·s and 1.098±0.111 mPa·s, respectively (p=0.782). There was no relationship between plasma viscosity levels and the JAK2 V617F mutation in polycythemia vera. In correlation analyses, fibrinogen was cor-related with plasma viscosity in both groups (r=0.30, r=0.15). In addition, the erythrocyte sedimentation rate was cor-related with plasma viscosity in both groups (r=0.230, r=0.272).
Conclusion: We were unable to demonstrate a relationship between plasma viscosity and the JAK2 V617F mutation in patients with polycythemia vera. This study shows that plasma viscosity is affected by fibrinogen and other acute-phase reactants.
Keywords: Plasma viscosity, JAK2 V617F, fibrinogen, erythrocyte sedimentation rate, polycythemia vera
Current Issue Vol 5 · Iss 3
